To Make Medicine That No One Has Ever Seen Before

Thorsten Gressling ()
Additional contact information
Thorsten Gressling: Distruptive Technology, Bayer AG

A chapter in Work and AI 2030, 2023, pp 313-321 from Springer

Abstract: Abstract “The use of artificial intelligence is indispensable for the development of new therapies. AI approaches are applied along the entire value chain—from the discovery and optimisation of new active ingredients, to the conduct of clinical trials, to pharmacovigilance, to name just a few examples.” The search for new active substances has already been influenced by learning algorithms decades ago. Statistical methods—AI of the second generation—have also been in use for a long time in drug development, in the evaluation of studies and in production. Recently, however, new fields of application have been opened up by the emergence of deep learning, which go beyond the medical-chemical domain and enable new possibilities of cross-functional use for large companies. This article shows the way from isolated applications to a new, holistic vision of value creation at Bayer AG.

Date: 2023
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-3-658-40232-7_35

Ordering information: This item can be ordered from
http://www.springer.com/9783658402327

DOI: 10.1007/978-3-658-40232-7_35

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().